Albert Hofmann discovered LSD and isolated psilocybin. His pharmaceutical research opened an experience that his profession lacked the means to contain. He spent the rest of his life asking for a seriousness that prohibition and casual use each failed to provide.
The Pharmakon develops the wider operation of a substance that can heal, poison, or open a threshold. Hofmann gives that operation its twentieth-century recovery and ethical vocabulary.
Swiss Chemist
Albert Hofmann (1906–2008) was born in Baden, Switzerland, the son of a factory worker. He studied chemistry at the University of Zurich and completed his doctorate in 1929. His subject was the structure of chitin, the polysaccharide that forms insect exoskeletons and fungal cell walls.
He joined Sandoz Laboratories in Basel that year and remained there throughout his professional career. In 1971, he retired as head of its natural products department. His work belonged to a patient research tradition that studied plant alkaloids and the relation between molecular structure and activity. Chemists extracted botanical compounds and sought their therapeutic uses.
Early work on Scilla maritima and digitalis glycosides established Hofmann’s competence in this field. LSD and psilocybin later carried his significance into the history of the pharmakon. A career within pharmaceutical chemistry became a recovery of sacramental access.
Sandoz’s commercial interest in ergot alkaloids led to the assignment that produced LSD. The fungus Claviceps purpurea produces these compounds. Midwives had long used ergot to control postpartum hemorrhage. The same substance poisoned populations through the medieval epidemics called St. Anthony’s fire.
Sandoz sold purified ergot alkaloids and asked Hofmann to extend the line through new derivatives. He modified known active molecules, tested their activity, and developed promising compounds into medicines. The program produced Methergine, which replaced older ergot preparations as the standard treatment for postpartum hemorrhage and remains in use.
From Synthesis to Discovery
Hofmann synthesized LSD-25 in 1938. The “25” identifies its position as the twenty-fifth compound in a series of lysergic acid derivatives. Lysergic acid supplies the core structure common to most ergot alkaloids. LSD is its diethylamide, formed through substitution at the acid’s amide group.
Hofmann intended to produce a circulatory and respiratory stimulant similar to nikethamide. That commercial stimulant shared a diethylamide group. Sandoz’s animal screening found restlessness and increased pulse, but no effect strong enough to warrant development. The compound was filed with other commercially unpromising derivatives, and Hofmann continued elsewhere.
Five years later, he returned to LSD-25 against the usual practice of leaving abandoned compounds alone. He called the decision a “peculiar presentiment.” In his later account, he could not explain why he chose to make it again. The return brought the discarded molecule back to its chemist.
He resynthesized it on April 16, 1943. During crystallization, he felt unease and experienced a vivid imagination. He first suspected solvent vapors, then described “an uninterrupted stream of fantastic pictures, extraordinary shapes with intense, kaleidoscopic play of colors.” The episode lasted approximately two hours.
Hofmann concluded that the substance had affected him and decided to test that conclusion through self-experimentation. Mid-twentieth-century pharmaceutical researchers used this method for effects that animal models could not readily assess. The route of his initial exposure remains unresolved.
Bicycle Day
On April 19, 1943, at 4:20 in the afternoon, Hofmann took 250 micrograms of LSD-25 in his laboratory. Comparison with other ergot alkaloids had led him to expect this to be the lowest amount with a detectable effect. His calculation was off by approximately a factor of five. The dose was strongly psychoactive, and the first intentional human LSD experience began without adequate preparation.
Within forty minutes, he recorded dizziness, anxiety, visual disturbances, and a desire to laugh in his laboratory notebook. He asked his assistant to escort him home. Wartime vehicle restrictions required them to travel by bicycle from Sandoz to his home in Bottmingen. The effects intensified during the journey.
That ride became a founding event of the Western psychedelic tradition. Communities formed around its inheritance now observe “Bicycle Day” each April 19. Their tradition followed an ordeal its first participant had to survive before he could understand it.
In LSD: My Problem Child, Hofmann describes stationary objects appearing to move and familiar streets becoming alien territory. Cycling through a Swiss suburb carried a sense of cosmic threat. At home, a physician found his vital signs normal despite his extraordinary mental state. Hofmann believed that he was dying.
As the peak passed, he recognized an experience of lasting importance. The compound exceeded his intention to make a stimulant. It opened states for which conventional pharmacology had no adequate account. His report to the Sandoz directors described profound alterations of consciousness at unusually low doses and proposed further psychiatric research.
Sandoz distributed LSD worldwide as Delysid. Its recommended research use induced temporary psychotic-like states. Researchers could study those states inwardly through self-experimentation or observe them in patients. Between 1943 and 1966, thousands of researchers, clinicians, and experimental subjects legally received the compound. Regulatory pressure led Sandoz to withdraw it in 1966.
Several thousand peer-reviewed papers from that period examined LSD’s effects, mechanism, and therapeutic potential. The literature is still being cataloged. German, French, and other non-English papers from the pre-digital archive remain difficult for the modern renaissance to recover. Their findings form part of the inheritance behind today’s renewed research.
The Mexican Mushroom Journey
R. Gordon Wasson initiated Hofmann’s second major contribution to the pharmakon tradition. In 1955, Wasson attended a velada, a healing ceremony, with the Mazatec curandera María Sabina in Huautla de Jiménez, Oaxaca. He consumed sacred mushrooms and recognized that a substance mediated the experience. In 1957, he arranged for samples to reach Hofmann’s Basel laboratory.
Hofmann’s team isolated psilocybin from Psilocybe mexicana in 1958. They identified it as 4-phosphoryloxy-N,N-dimethyltryptamine, a prodrug that the body converts to psilocin. Hofmann then synthesized it to confirm its structure and supply it without mushroom cultivation. Sandoz became the first legal commercial supplier of pharmaceutically pure psilocybin. Timothy Leary’s early Harvard studies used that material.
Hofmann traveled with Wasson to Mexico in 1962 and offered María Sabina synthetic psilocybin tablets. Wasson’s Life article had made her famous. Foreign seekers then inundated her community, damaging her village and lineage through their unregulated presence.
She consumed the tablets within the ceremonial setting and confirmed that they opened the same state as the mushrooms. The synthesized compound carried the botanical sacrament’s effect. Its transfer was recovery and extraction at once. The molecule entered industrial custody while its ceremonial, communal, and ethical vessel remained behind.
The Road to Eleusis
In 1977, Hofmann, Wasson, and the classicist Carl Ruck began work on the Eleusinian mysteries. Their jointly authored The Road to Eleusis appeared in 1978. It proposed an ergot preparation as the kykeon, the sacramental drink taken before initiates entered the telesterion. In this hypothesis, Claviceps purpurea grew on the barley used for the drink.
Hofmann supplied the chemistry. Water-soluble ergot alkaloids, including ergonovine and ergine, could be extracted from infected barley through a simple aqueous preparation. He demonstrated psychoactive effects at appropriate doses and considered how preparation could manage ergot’s toxicity. A hereditary priestly lineage with millennia of experience could develop such techniques. The chemical reconstruction does not recover the lost recipe or establish its complete dose and operation.
The proposed preparation connects his modern discovery with the Eleusinian lineage. LSD-25 is an ergot derivative, a modern refinement of the chemistry the hypothesis places with the hierophants in 1500 BCE. That material relation is literal: the same fungus, class of alkaloids, and basic mechanism. The historical reconstruction remains distinct from that chemical continuity.
Hofmann’s 1943 experience recovered an access point through modern pharmaceutical chemistry. Western civilization had lost its operational lineage with the destruction of the Eleusinian sanctuary in 396 CE. Approximately fifteen hundred years separated the loss and return. The cycle carries this passage from a destroyed lineage to recovery through another means.
Hofmann regarded the Eleusis hypothesis as his most important work. In later interviews, he described LSD as given to him, received rather than invented. Its arrival coincided with Western civilization’s exhaustion of its purely rationalist resources. He regarded that timing as consequential.
He also opposed the uses that failed to meet the molecule’s seriousness. Uncontrolled counterculture use helped produce the prohibition era. Later medicalization risked absorbing the substance into a pharmaceutical account unable to accommodate its full operation.
Hofmann died at 102 in his Swiss home in 2008. He had seen the beginnings of the contemporary renaissance and expressed cautious hope for a mature tradition. Such a tradition would need to handle what the molecule opened with the seriousness his lifetime of interpretation had developed.
The Figure of the Chemist
Hofmann embodies the scientist-initiate, whose institutional credibility carries a depth the institution cannot recognize. His practice was that of a credentialed research chemist. The discovery exceeded what his institution could accommodate, and its meaning occupied the rest of his life.
The sacrament returned through pharmaceutical orthodoxy’s own apparatus. That apparatus had organized the exclusion of what the molecule opened. A productive chemist at one of its central institutions recovered the substance that exposed its limits. Competence within the approved discipline made the breakthrough possible.
Parsons at JPL gives the pattern another carrier. A practicing Thelemite supplied rocket chemistry that helped found the American space program. His esoteric and scientific work formed one activity. Hofmann at Sandoz supplied the pharmaceutical counterpart.
Both men worked as competent, productive employees within their institutions. Approved research produced discoveries whose consequences threatened the limits under which that research had been authorized. The institutions would have prevented those discoveries had they understood what their own work was bringing into form.
The Molecule Returned When the Vessel Was Ready
Hofmann’s discovery restored pharmacological access to the Western sacramental threshold for the first time since the destruction of Eleusis. The abandoned twenty-fifth compound called its chemist back. Presentiment, unexplained exposure, and the precisely survivable ordeal of Bicycle Day formed one threshold recovery. He spent sixty-five years interpreting what had returned.
The molecule arrived when its vessel and the cycle could receive it. The ride became an uncontained initiation of the returning sacrament. No teacher, temple, or lineage stood ready to hold it. Hofmann had no language adequate to the opening, but supplied a stability that the missing temple could not provide.
His mature judgment completes the event: LSD was received rather than invented. Chemistry recovered the key before modern culture recovered the vessel capable of holding it. The opening therefore returned with a task that outlasted its first chemical discovery.
References
Grinspoon, Lester, and James B. Bakalar. Psychedelic Drugs Reconsidered. Basic Books, 1979.
Hagenbach, Dieter, and Lucius Werthmüller. Mystic Chemist: The Life of Albert Hofmann and His Discovery of LSD. Synergetic Press, 2013.
Hofmann, Albert. LSD: My Problem Child. McGraw-Hill, 1980.
Hofmann, Albert. Insight Outlook. Humanics New Age, 1989.
Hofmann, Albert, and R. Gordon Wasson. Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers. Healing Arts Press, 1979.
Lee, Martin A., and Bruce Shlain. Acid Dreams: The Complete Social History of LSD. Grove Press, 1985.
Pahnke, Walter N., and William A. Richards. “Implications of LSD and Experimental Mysticism.” Journal of Religion and Health 5, no. 3 (1966): 175–208.
Pollan, Michael. How to Change Your Mind. Penguin Press, 2018.
Stoll, Werner A. “Lysergsäure-diäthylamid, ein Phantastikum aus der Mutterkorngruppe.” Schweizer Archiv für Neurologie und Psychiatrie 60 (1947): 279–323.
Wasson, R. Gordon, Albert Hofmann, and Carl A.P. Ruck. The Road to Eleusis: Unveiling the Secret of the Mysteries. Harcourt Brace Jovanovich, 1978.